Ann: Annual Report to shareholders, page-69

First 69 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

03/10/22

11:38

Post #: 63997368
Share

Originally posted by RoyE: ↑

Both the Chairman's letter and the MD's letter mention new product opportunities of HPA and nanotechnologies. Neither mention concrete apps which is interesting. Both downplay the scaling back of the plant size as contemplated in the DFS with the Chairman commenting as follows in reference to the scale down in the plant size versus DFS:

'Importantly however, it remains the firm intention of Andromeda’s Board and Management to deliver the Project’s production and financial outcomes, as outlined in the DFS.'

Of course their intention is to ultimately deliver as outlined in the DFS, this is obvious - generally, all businesses want to grow and sell as much as possible. The reality is though that ADN have made the conscious decision to start smaller (in the full knowledge that this would provoke a shareholder backlash), as currently they simply don't have the sales to underpin the original plant size as contemplated in the DFS. And it's not like they haven't been trying to sell product - they have been promoting the products for quite some time now.

Additionally, they tried to deliver the market sensitive news re plant downsizing in a benign announcement primarily about ordering long lead time items, which IMO was completely misleading. When they did this, for me all trust in management was lost.

IMO the MD's position at ADN is untenable - IMO, if you are an MD of a listed entity it is incumbent on you to choose your words very carefully and strive to under promise and over deliver, not the other way around.

Enterprise value of ADN is now approx. $100 million and I don't have an opinion re whether this offers value or not - $100 million is still a very significant Enterprise value. They may surprise and pull a rabbit out of the hat (IMO unlikely but not impossible). For me, I won't invest when I don't believe in the management and I still see more attractive risk versus reward investments elsewhere.

GLTA & DYOR

Expand

"Neither mention concrete apps which is interesting"

LOL

ADN Price at posting: 4.1¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

FFM

Firefly positioned for copper growth in Canada ahead of resource update

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 153 more messages in this thread...

First 69 Last

Add ADN (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change 0.000(0.00%)		Mkt cap ! $27.14M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.8¢	$177.5K	22.19M

Buyers (Bids)

No.	Vol.	Price($)
15	16345413	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	15152155	14

View Market Depth

No.	Vol.	Price($)
15	16345413	0.008
73	31713030	0.007
56	20707989	0.006
21	13971789	0.005
7	8025000	0.004

Price($)	Vol.	No.
0.009	15152155	14
0.010	7942677	11
0.011	14396522	8
0.012	13445921	6
0.013	2597253	4

Last trade - 11.45am 03/10/2024 (20 minute delay)

ADN (ASX) Chart

Ann: Annual Report to shareholders, page-69

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Firefly positioned for copper growth in Canada ahead of resource update

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Annual Report to shareholders, page-69

Top Stories

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Firefly positioned for copper growth in Canada ahead of resource update

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News